GLP-1 TV
The $50 Medicare Zepbound, Wegovy Rumor! What's Actually Happening?
Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
The speaker of the channel the channel says that, as of March 8, 2026, there are no $50 per month Zepbound or Wegovy prescriptions available through Medicare for obesity. He explains that Medicare generally does not cover these drugs when prescribed for obesity, and that federal law bars Medicare patients from using manufacturer savings cards. He says list price for the branded pens is about $1,000 a month.
Published by DOWNSIZED on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
According to the video, the $50 figure traces to a November 2025 White House announcement on most favored nation pricing, with agreements involving Eli Lilly and Novo Nordisk. It refers to the CMS BALANCE model, a pilot from the CMS Innovation Center. He says a Medicare bridge demonstration is planned for July 2026, with a copay of around $50 per month, but eligibility criteria had not been released. Medicaid agencies could join in May 2026, Part D plans in January 2027, and testing runs through December 2031. He stresses that participation is voluntary for manufacturers and plans.
He then covers the two legal barriers: the 2003 Part D law that excludes weight loss drugs, and the anti-kickback statute behind the savings card ban. He describes the Treat and Reduce Obesity Act (TROA) as repeatedly introduced since 2013 without passing. Options he lists are a covered diagnosis such as type 2 diabetes, manufacturer patient assistance programs, and cash pay through NovoCare, Lilly Direct, or telehealth with compounding. He and his wife are not doctors, and he says this is not medical advice.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:02 The speaker says that as of March 8, 2026, no $50 per month Zepbound or Wegovy is available through Medicare for obesity, and savings cards cannot be used.
- 0:04 He traces the $50 figure to a November 2025 White House announcement and the CMS BALANCE model, which he says has not yet started.
- 0:08 He says the Medicare bridge demonstration is planned for July 2026 with a copay of around $50 per month, but eligibility criteria were not yet released.
- 0:10 According to the video, participation is voluntary for manufacturers and Part D plans, and no Medicare plans had opted in.
- 0:11 He explains that a 2003 law excludes weight loss drugs from Part D and the anti-kickback statute blocks savings cards.
- 0:15 He lists options to discuss: a covered diagnosis like type 2 diabetes, patient assistance programs, and cash pay programs.
Key moments
Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Wegovy and Zepbound
Questions this video answers
Can Medicare patients get Zepbound or Wegovy for $50 a month?
According to the video, not as of March 8, 2026. The $50 copay is tied to a bridge demonstration that CMS plans to launch in July 2026, and eligibility criteria had not been released.
Why can't Medicare patients use Zepbound or Wegovy savings cards?
The speaker says the anti-kickback statute, a federal law meant to prevent financial inducements within federal health care programs, prohibits Medicare patients from using manufacturer savings cards.
What is the CMS BALANCE model for GLP-1 drugs?
The speaker describes it as a pilot from the CMS Innovation Center testing whether wider access to obesity medications plus lifestyle support improves outcomes and lowers long-term costs. He says participation is voluntary for manufacturers and plans, and testing runs through December 2031.
What options do Medicare patients have for GLP-1 drugs right now?
He lists asking a doctor about a covered diagnosis such as type 2 diabetes, manufacturer patient assistance programs, and cash pay through NovoCare, Lilly Direct, or telehealth. He says cash pay is usually lower, around $499 at the highest doses.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Medicare's New GLP-1 Rule: The BMI Surprise You Need to KnowIn this podcast episode, host Anna Reisdorf, a registered dietitian, talks with the speaker, a physician assistant who works in obesity medicine, about the Medicare GLP-1 bridge program that starts July 1st, 2026.- What a GLP-1 costs at every program we trackToday’s lowest is $39/mo. Every program ranked by price alone. Compounded drugs are not FDA-approved.
$50 GLP-1s? Here’s How the Medicare Bridge WorksThe speaker of the channel gives a plain-language overview of the Medicare GLP-1 Bridge Short-Term Demonstration.
GLP-1 Drugs Are About to Destroy Medicare CostsAccording to the video, Medicare will begin covering weight loss drugs such as Wegovy and Zepbound in July 2026 through a temporary route, and the speaker argues this could change the math behind Medicare premiums.
Medicare Finally Covers Weight Loss Meds —Weight Loss Doctor Explains The GLP-1 Bridge ProgramThe speaker, who describes herself as a board-certified internal medicine and obesity medicine doctor, explains a new Medicare program called the Medicare GLP1 bridge.
Trump Touts Medicare Coverage For Weight-Loss Drugs For $50 Per MonthIn this short clip from the channel upload, the speaker speaks at an event about drug prices.
Zepbound vs. Wegovy, CVS vs. Patients, and the Executive Order That Changes EverythingIn this weekly podcast episode from May 13, 2025, the speaker covers a new executive order on prescription drug pricing and CVS Caremark's move to prefer Wegovy over Zepbound.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Does Medicare cover GLP-1s? Ozempic, Wegovy and Zepbound, route by route
Yes, by two different routes. Medicare drug plans (Part D, including Medicare Advantage plans with drug coverage) cover Ozempic and Mounjaro for type 2 diabetes. For weight loss, the Medicare GLP-1 Bridge covers Wegovy (pen or pill), the Zepbound KwikPen and Foundayo for a $50 monthly copay from 1 July 2026 to 31 December 2027, if you meet CMS's BMI criteria. The catch: the Bridge runs outside Part D, so that $50 never counts toward your deductible or out-of-pocket cap.
- How much does Zepbound cost: $25 with coverage, $299 to $449 self-pay, $50 on Medicare
Zepbound costs as little as $25 a month if your commercial plan covers the single-dose pen and you use Lilly's savings card, which pays up to $100 a month and $1,300 a year. If your plan does not cover it, or you have no insurance, Lilly's self-pay KwikPen and vial run $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg with on-time refills. On Medicare, the GLP-1 Bridge covers the KwikPen for a $50 copay. Compounded tirzepatide starts at $69 on our board.
- The Zepbound savings card: two programs, not one
Lilly runs two different Zepbound savings programs and which one you get depends on whether your insurance covers Zepbound at all. If it does, the card can bring you to as little as $25 a month, capped at $100 of savings for a one-month fill. If your plan does not cover it, you are on a different program that puts a one-month single-dose pen fill at $499, or a KwikPen fill at $299 to $449 by dose. Separately, Lilly sells the KwikPen and vial direct at $299 to $699 by dose, and government beneficiaries are excluded from the card entirely.
Next steps
Wegovy prices
Find more like it
Dose changeWeigh-in and resultsCost and insurance
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















